Evidence map›Paper›PMID 36225773›Full record

ArticleFrontiers in public health2022

Instrument referral criteria for PlusoptiX and SureSight based on 2021 AAPOS guidelines: A population-based study.

Qi Yan, Rui Li, YingXiao Qian, Xiao Lin, Hui Zhu, Yue Wang, Xiaoyan Zhao, Xiaohan Zhang, Qigang Sun, Qingfeng Hao and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Retinoscopes: Past and present.World journal of methodology · 2024
    Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Qi YanDepartment of Ophthalmology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Rui LiDepartment of Ophthalmology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
YingXiao QianDepartment of Ophthalmology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Xiao LinCollege of Optometry, University of Houston, Houston, TX, United States.
Hui ZhuDepartment of Ophthalmology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Yue WangDepartment of Ophthalmology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Xiaoyan ZhaoDepartment of Ophthalmology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Xiaohan ZhangDepartment of Ophthalmology, Wuxi Children's Hospital, Wuxi, China.
Qigang SunDepartment of Ophthalmology, Nanjing International Hospital, Nanjing, China.
Qingfeng HaoDepartment of Ophthalmology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Haohai TongThe Second Affiliated Hospital, Zhejiang University School of Medicine, Eye Center, Hangzhou, China.
Yue ZhuFourth School of Clinical Medicine of Nanjing Medical University, Nanjing, China.
Zhitong LiFourth School of Clinical Medicine of Nanjing Medical University, Nanjing, China.
Yan ZhuFourth School of Clinical Medicine of Nanjing Medical University, Nanjing, China.
Hu LiuDepartment of Ophthalmology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Dan HuangDepartment of Ophthalmology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNSecond Affiliated Hospital of Nanjing Medical University · CNChangzhou No.2 People's Hospital · CNSecond Affiliated Hospital of Zhejiang University · CNUniversity of Houston · USWuxi People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The study aims to assess two refractive instrument-based methods of vision screening (SureSight and PlusoptiX) to detect refractive amblyopia risk factors (ARFs) and significant refractive errors in Chinese preschool children and to develop referral criteria according to the 2021 AAPOS guidelines. Methods: Eye examinations were conducted in children aged 61 to 72 months ( Results: A total of 1,173 children were tested with comprehensive eye examinations. When the referral numbers based on the 2013 (43/3.67%) and 2021 (42/3.58%) AAPOS guidelines were compared, significant differences between the values of astigmatism (72.09 vs. 52.38%) and anisometropia (11.63 vs. 38.10%) were found. The 95% limits of agreement (LOA) of the spherical value and the cylindrical value between PlusoptiX and CR were 95.08 and 96.29%. It was 93.87 and 98.10% between SureSight and CR. Considering refractive failure levels, the ROC curves obtained the optimal cut-off points. However, the PlusoptiX and the SureSight showed lower efficiency in hyperopia (Youden index, 0.60 vs. 0.83) and myopia (Youden index, 078 vs. 0.93), respectively. After adjusting the above cut-off points, the optimized NES (Nanjing Eye Study) referral criteria for myopia, hyperopia, astigmatism, and anisometropia were -0.75, 1.25, -1.0, and 0.5 with PlusoptiX and -1.25, 2.75, -1.5, and 0.75 with SureSight. Conclusions: SureSight and PlusoptiX showed a good correlation with CR and could effectively detect refractive ARFs and visually significant refractive errors. There were obvious advantages in detecting hyperopia using SureSight and myopia using PlusoptiX. We proposed instrumental referral criteria for age-based preschool children based on AAPOS 2021 guidelines.

Indexed as

AmblyopiaAnisometropiaAstigmatismHyperopiaMyopiaRefractive ErrorsChild, PreschoolHumansMydriaticsReferral and ConsultationReproducibility of ResultsSensitivity and SpecificityMydriaticsAAPOS 2021amblyopia risk factorsfailure criteriareferral criteriavision screening

Identifiers

PMID36225773
PMCPMC9548965
OpenAlexW4297236828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.